Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Glioblastoma

Carcinoma, Transitional Cell

Carcinoma, Non-Small-Cell Lung

Head and Neck Neoplasms

Salivary Gland Neoplasms

Breast Neoplasms

Urothelial Bladder Carcinoma

Localized Muscle Invasive Bladder Urothelial Carcinoma

Ovarian Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Breast Neoplasms

Cholangiocarcinoma, Klatskin Tumor

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Endometrial Neoplasms

Triple Negative Breast Neoplasms

Uterine Cervical Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Advanced Breast Cancer

Clinical Trials

InCITe

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Sacituzumab Govitecan in Recurrent Glioblastoma

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

TianjinCIH

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

SIMONE

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

SATROPIN

STORM

ADJUNCT

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC